Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine

Trial Profile

Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Seliciclib (Primary)
  • Indications Cushing syndrome
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 30 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 30 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 11 Jan 2016 According to Cyclacel Pharmaceuticals media release, the company expects to report data from this trial in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top